Childhood Cancers Flashcards
Chemo agents + Long term effects
Doxorubicin- Cardiotoxic
Cisplatinum - Nephrotoxic and Ototoxic
Carboplatinum -nephrotoxic
Vincristine - Neurotoxic
Etoposide - Secondary malignancy
Dactinomycin - Hepatotoxic ( Veno - occlusive disease of liver)
Bleomycin - Pulmonary toxicity (fibrosis)
Treatment of Tumor Lysis
Preventative: Hyperhydration - 2.5 L/m2 of IV fluid, allopurinol or urate oxidase (Rasburicase)
Phosphate excretion: Aluminum hydroxide
Treat symptomatic hypercalcemia
Dialysis if progressive renal failure, K>6mEq/l, PO4 >6mg/dl, Oliguria, Anuria and volume overload, symptomatic hypocalcemia, hypertension
Hyperleukocytosis
WCC >100 x 10^9/l
More common in AML than ALL
Clinically significant hyperleukocytoses
WCC> 200x10^9/l
AML - >50x 10^9/l
Signs and Symptoms of Hyperleukocytosis
CNS - Vision loss, diplopia, delirium, stupor, papilledema, coma
RS - Orthopnea , Dyspnea, Tachypnea, Hypoxia
Genitourinary- Oliguria, anuria, priapism
DIC, retinal hemorrhages, renal vein thrombosis
Management of patients with Hyperleukocytosis
Supportive care: Hyper-hydrate with 2.5-3 L/m2 of fluid, prevent TLS, give allopurinol/rasburicase.
If patient is asymptomatic, do chemotherapy
If patient is symptomatic or TLC >300,000/mm3 (AML) or >100,000mm3 (ALL)- Chemotherapy + Leukapheresis
Management of patients with Hyperleukocytosis
Coagulopathy correction
Asymptomatic patients: HB>6-7 g/dl: No RBC transfusion
Hb<5-6g/dl or signs of Congestive heart failure: RBC transfusion
Symptomatic
Platelets <20000/mm^3 - Platelets transfusion
Management of Hyperleukocytosis
Hyper-hydration - N/S (0.9%) at 3l/m2 IV. Monitor urine output
Start allopurinol 100mg/m2/day in divided doses
Platelet transfusion if platelet count <20 and reduce risk of IntraCranial Hemorrhage
Whole blood transfusion only if symptomatic anaemia or Hb<6. avoid packed cells - causes hyper viscosity
FFP transfusion with Vit K if coagulopathy present
Exchange blood transfusion (Leukopheresis)
Start steroids for acute leukemia, NHL
Hydroxyurea in CML/AML
Start chemotherapy
Management of Febrile Neutropenia
Blood cultures
Urinalysis and culture
Culture of septic lesions
CSF culture if there’re signs of meningism
CXR if respiratory signs
Give Ceftriaxone and Gentamycin - 1 line
Meropenam - 2 line
Vancomycin- 3 line
If there’s prolonged FN >96 hours - invasive fungal infection
Or viral infection or TB
Good prognostic indicators for ALL
Age - 1 to 9
WBC x10^9 - 10
Immunophenotype - Pre-B cell
Genetics - Hyperploidy, DNA index >1.16
CNS Status - CNS 1
Race - Caucasians
Sex - Female
Organomegaly - Absent
Mediastinal mass - Absent
Response to early treatment- Rapid
MRD( end of induction) - <0.01
Intermediate Prognostic factors for ALL
Age - <10^a
WBC x10^9 - >/= 50^a
Immunophenotype - T cell
Genetics - Diploid
CNS Status - CNS 2^a
MRD( end of induction) - 0.01 to 0.99%
Unfavorable prognostic indicators for ALL
Age - <1 and MLL+
Genetics - Hypoploidy <44 DNA<1.16
CNS Status - CNS 3
Race - Black
Sex - Male
Organomegaly - Present
Mediastinal mass - Present
Response to early treatment- Slow
MRD( end of induction) - <1%
Treatment of ALL
Start with good counselling about condition and treatment (takes 2 years)
Supportive care – packed cells, platelet transfusion.
High fever/Febrile neutropenia and possible septicaemia-antibiotics with Blood cultures.
Allopurinol 10mg/kg/day
Fluid intake of 2-3L/m2/day
Manage hyperleukocytosis
Support to prevent and ameliorate tumour lysis syndrome.
Differential Diagnosis of ALL
AML
Aplastic anaemia
Myelofibrosis
Infectious mononucleosis
Juvenile idiopathic arthritis
Osteomyelitis
Infiltration of the bone marrow- neuroblastoma, rhabdomyosarcoma, Ewing sarcoma
Laboratory Investigations for ALL
FBC and blood film comment (Blasts in peripheral blood)
Bone marrow aspirates and trephine- Morphology (Blast >25%), histochemistry, immunophenotyping, cytogenetics.
Chest x-ray - Mediastinal mass
Blood chemistry – LFTs and RFT
CSF – blasts and cells (Lumbar Puncture)
Coagulation profile
HIV screen
Treatment Strategies of ALL - Induction and Consolidation
Induction: usually in Haematologic malignancies. A combination of high dose drugs to induce complete response when initiating a curative regimen(Vinc, Doxo, L-Aspar, Steroid, IT MTX/Ara C - MAVDAS)
Consolidation: given after induction has achieved a complete remission. Prevents re-proliferation of leukaemic cells. Repeated to increase cure rate or prolong survival. (Ara C, Cyclo, Doxo, Etop - CADE)
Ara-C is cytarabine
IT-MTX - Methotrexate
Treatment Stategies for ALL - Delayed Intensification and Maintenance
Intensification: after complete remission is achieved, same agents used in induction or diff agents are given at high doses to effect better cure rate or longer remission (Repeat Induction and Consolidation)
Maintenance: Combination, low dose given on long term basis in remission to prevent re-growth of residual cancer cells( 6MP, MTX, Vinc, steroids for 2 – 3yrs. Females - 2 y. Males - 3 y
MMVS
6MP - Mercaptopurine
Acute Complications from ALL Treatment
Tumour lysis syndrome
Renal failure
Sepsis
Bleeding - ‘cause of low thrombocytes from treatment
Thrombosis
Encephalopathy
Seizures
Typhilitis- neutropenic enterocolitis
Chronic Complications of ALL Treatment
Secondary malignancy
Short stature
GH deficiency
Learning disability
Cognitive defects
Neuropathy
Presenting features of AML
Leukemia Cutis
Gingival hypertrophy
Chloroma
Predisposing factors to AML
Down’s syndrome
Fanconi anaemia
Diamond-Blackfan syndrome
MDS and myeloproliferative syndrome
Ionizing radiation treatment
Chemotherapy- Cyclo, ifosfamide, etoposide, chlorambucil.
When is the prognosis for AML poor?
WBC > 100,000/mm3
2o AML - For example following treatment of ALL with etoposide
When is prognosis for AML good?
Down syndrome
M3 Subtype
How is AML treated?
*Ara-C, Doxorubicin. Etoposide (CED), Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine)
*All Trans Retinoic Acid for M3
*High dose cytarabine
*Stem cell transplant for relapse
What is the cytogenic abnormality in CML?
Cytogenic Abnormality - Presence of Philadelphia Chromosome, which results from the translocation of chromosomes 9 and 22 (t(9;220) resulting in BCS-ABL fusion protein.